CO2022001991A2 - Un método para preparar ivosidenib y un intermediario del mismo - Google Patents

Un método para preparar ivosidenib y un intermediario del mismo

Info

Publication number
CO2022001991A2
CO2022001991A2 CONC2022/0001991A CO2022001991A CO2022001991A2 CO 2022001991 A2 CO2022001991 A2 CO 2022001991A2 CO 2022001991 A CO2022001991 A CO 2022001991A CO 2022001991 A2 CO2022001991 A2 CO 2022001991A2
Authority
CO
Colombia
Prior art keywords
ivosidenib
preparing
synthesize
application relates
current application
Prior art date
Application number
CONC2022/0001991A
Other languages
English (en)
Inventor
Jacob Paul Sizemore
Shijie Zhang
Nha Huu Vo
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CO2022001991A2 publication Critical patent/CO2022001991A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La solicitud actual se refiere a un método para preparar solvato de etanol cristalino sustancialmente y diaestereoméricamente puro del Compuesto IIa y su uso para sintetizar Ivosidenib.
CONC2022/0001991A 2019-08-08 2022-02-24 Un método para preparar ivosidenib y un intermediario del mismo CO2022001991A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884480P 2019-08-08 2019-08-08
PCT/US2020/045368 WO2021026436A1 (en) 2019-08-08 2020-08-07 A method for preparing ivosidenib and an intermediate thereof

Publications (1)

Publication Number Publication Date
CO2022001991A2 true CO2022001991A2 (es) 2022-07-29

Family

ID=74504162

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001991A CO2022001991A2 (es) 2019-08-08 2022-02-24 Un método para preparar ivosidenib y un intermediario del mismo

Country Status (29)

Country Link
US (1) US20230025411A1 (es)
EP (1) EP4010331B1 (es)
JP (1) JP2022544143A (es)
KR (1) KR20220061971A (es)
CN (1) CN114555584A (es)
AU (1) AU2020327013A1 (es)
BR (1) BR112022002253A2 (es)
CA (1) CA3150028A1 (es)
CL (1) CL2022000310A1 (es)
CO (1) CO2022001991A2 (es)
CR (1) CR20220090A (es)
DK (1) DK4010331T3 (es)
EC (1) ECSP22016924A (es)
ES (1) ES2967909T3 (es)
FI (1) FI4010331T3 (es)
HR (1) HRP20231618T1 (es)
HU (1) HUE064193T2 (es)
IL (1) IL290377A (es)
LT (1) LT4010331T (es)
MA (1) MA56783B1 (es)
MD (1) MD4010331T2 (es)
MX (1) MX2022001619A (es)
PE (1) PE20221761A1 (es)
PL (1) PL4010331T3 (es)
PT (1) PT4010331T (es)
RS (1) RS64934B1 (es)
SI (1) SI4010331T1 (es)
TW (1) TW202120491A (es)
WO (1) WO2021026436A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
WO2019104318A1 (en) * 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ivosidenib
CN112367995A (zh) * 2018-07-06 2021-02-12 安吉奥斯医药品有限公司 艾伏尼布形式和药物组合物
WO2020127887A1 (en) * 2018-12-21 2020-06-25 Sandoz Ag Process for the preparation of an intermediate product of ivosidenib

Also Published As

Publication number Publication date
PL4010331T3 (pl) 2024-03-11
HUE064193T2 (hu) 2024-02-28
MX2022001619A (es) 2022-07-19
MD4010331T2 (ro) 2024-03-31
EP4010331B1 (en) 2023-10-04
CL2022000310A1 (es) 2022-11-25
LT4010331T (lt) 2023-11-10
IL290377A (en) 2022-04-01
FI4010331T3 (fi) 2023-12-28
PE20221761A1 (es) 2022-11-11
KR20220061971A (ko) 2022-05-13
BR112022002253A2 (pt) 2022-07-05
ES2967909T3 (es) 2024-05-06
HRP20231618T1 (hr) 2024-03-15
US20230025411A1 (en) 2023-01-26
CR20220090A (es) 2022-08-24
JP2022544143A (ja) 2022-10-17
SI4010331T1 (sl) 2024-02-29
TW202120491A (zh) 2021-06-01
PT4010331T (pt) 2024-01-08
CA3150028A1 (en) 2021-02-11
EP4010331A1 (en) 2022-06-15
AU2020327013A1 (en) 2022-03-24
CN114555584A (zh) 2022-05-27
WO2021026436A1 (en) 2021-02-11
ECSP22016924A (es) 2022-06-30
DK4010331T3 (da) 2023-12-18
RS64934B1 (sr) 2023-12-29
MA56783B1 (fr) 2023-10-31

Similar Documents

Publication Publication Date Title
WO2020047004A3 (en) Methods of generating an array
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
EP3752602A4 (en) METHOD OF GENERATING CELLS OF THE T CELL LINE
AU2019222480A8 (en) Improved yeast for ethanol production
CO2021014022A2 (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
DOP2019000290A (es) Inhibidores de quinasa y usos de los mismos
EA202091979A1 (ru) Кристаллические формы и способы получения кристаллических форм соединения
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
MX2020004869A (es) Metodo para preparar derivado de benzofurano.
BR112022011946A2 (pt) Derivado de triazolopiridazina, método de preparação para o mesmo, composição farmacêutica do mesmo, e uso do mesmo
EP3675272A4 (en) SECONDARY BATTERY STATIC PRESSURE TEMPLATE AND PROCESS FOR ADJUSTING THE INTERNAL PRESSURE OF A SECONDARY BATTERY BY MEANS OF THE LATTER
CO2022009068A2 (es) Composición para la inhibición de la producción de hmf que comprende disacárido de alulosa
CR20200168A (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
MX2020010655A (es) Metodo para la preparacion de una 1,2,4-triazolona 2,4,5-trisustituida.
CO2022001991A2 (es) Un método para preparar ivosidenib y un intermediario del mismo
CL2021001511A1 (es) Novedosa psicosa-6-fosfato fosfatasa, composición para la producción de psicosa que comprende la misma y procedimiento para la producción de psicosa mediante el uso de la misma
MX2020008488A (es) Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo.
CL2022001612A1 (es) Tieniloxazolonas y análogos
CL2022001594A1 (es) Tiofenocarboxamidas sustituidas y sus derivados
MX2022002563A (es) Nuevo promotor y metodo para producir la sustancia deseada usando el mismo.
CO2022009062A2 (es) Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el uso de la misma
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
CR20230209A (es) Anticuerpos anti-ly6g6d y métodos de uso
BR112022008647A2 (pt) Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo